Skip to content
Inciteful Med

Medications and the Future of PKU Treatment

Last updated:

Pharmacological treatments for Phenylketonuria (PKU), such as Kuvan and Palynziq, can help lower blood phenylalanine levels and allow for a more flexible diet. Emerging research is also exploring gene therapy and engineered bacteria to further reduce the burden of strict dietary restrictions.

Key Takeaways

  • • Kuvan (sapropterin) acts as a chaperone to help stabilize existing enzymes in patients with mild or moderate PKU.
  • • Palynziq (pegvaliase) is a daily injection for adults with uncontrolled blood phenylalanine levels that uses a substitute enzyme to break down Phe.
  • • Patients taking Palynziq must carry an EpiPen at all times due to the risk of severe allergic reactions (anaphylaxis).
  • • Future therapies currently in clinical trials include gene therapy, mRNA therapy, and synthetic biotics (engineered bacteria).

While a restricted diet is the foundation of care, pharmacological treatments offer additional tools to manage Phenylketonuria (PKU). These medications are not a “cure,” but for many patients, they can lower blood phenylalanine (Phe) levels and allow for a more flexible diet [1][2].

Sapropterin Dihydrochloride (Kuvan)

Sapropterin is a synthetic version of BH4, the natural “spark plug” molecule that helps the PAH enzyme process Phe [3][4].

  • How it Works: It acts as a “chaperone,” stabilizing the patient’s existing enzyme so it can work more efficiently to convert Phe into tyrosine [3][5].
  • Who it Helps: It is most effective for patients with “mild” or “moderate” PKU who still have some enzyme activity [6][7]. Those with “classic” PKU, where the enzyme is completely non-functional, are typically non-responders [6].
  • The Test: To see if it works, doctors perform a loading test. A patient takes the medication for a period (ranging from 24 hours to 4 weeks), and if their blood Phe levels drop by 30% or more, they are considered a responder [3][6][8].
  • The Benefit: “Super-responders” may be able to significantly increase their natural protein intake and, in some cases, reduce or eliminate their reliance on medical formulas [9][10].

Pegvaliase (Palynziq)

Pegvaliase is an enzyme substitution therapy approved for adults (18+) who have uncontrolled blood Phe concentrations greater than 600 µmol/L on existing management [11][12].

  • How it Works: Unlike Kuvan, which helps your own enzyme, Palynziq uses a completely different enzyme (phenylalanine ammonia lyase or PAL) to break down Phe in the blood into harmless byproducts [11][13].
  • The Requirements: It is a daily subcutaneous (under the skin) injection [14][15].
  • The Risks: Because it is a foreign enzyme, the body’s immune system often reacts to it. The most serious risk is anaphylaxis, a severe allergic reaction that occurred in 4.6% to 21.6% of clinical trial participants [12][16].
  • Safety Protocol: Because of this risk, Palynziq is only available through a safety program called REMS. Patients must carry an auto-injectable adrenaline (EpiPen) at all times and may need an observer present during their initial doses [12][17][18].

Emerging Therapies and Research

The landscape of PKU treatment is rapidly changing, with several new approaches currently in clinical trials:

  • Gene Therapy: Researchers are testing ways to use viral vectors (like AAV) to deliver a healthy copy of the PAH gene directly into the liver cells, potentially providing a long-term or permanent solution [19][20].
  • mRNA Therapy: Similar to some modern vaccines, this approach uses mRNA to give the liver the instructions it needs to build functional PAH enzymes [21][1].
  • Synthetic Biotics: Scientists are developing “engineered bacteria” (like SYNB1934) that a patient swallows. These bacteria live in the gut and “eat” the Phe from food before it can ever enter the bloodstream [22][23].

These therapies aim to further reduce the “treatment burden” of PKU, moving toward a future where strict dietary restriction may no longer be the only option [2][24].

Frequently Asked Questions

Am I a candidate for Kuvan?
Kuvan works best for patients with mild or moderate PKU who still have some natural enzyme activity. Doctors determine if it will be effective for you by performing a trial period called a loading test to see if your phenylalanine levels drop.
How does Palynziq work for PKU?
Palynziq is an enzyme substitution therapy for adults that uses a completely different enzyme to break down phenylalanine in the blood. It requires daily under-the-skin injections and is prescribed for patients whose levels are not controlled by existing management.
What are the safety requirements and risks for taking Palynziq?
Because Palynziq introduces a foreign enzyme to your body, there is a risk of a severe allergic reaction called anaphylaxis. To ensure safety, patients taking this medication must carry an EpiPen at all times and enroll in a specialized monitoring program.
Can PKU be cured with gene therapy?
Gene therapy is not currently an available cure, but it is being actively researched in clinical trials. These future therapies aim to deliver healthy genes or mRNA directly to the liver to provide a more permanent solution for managing the condition.

Questions for Your Doctor

  • • Based on my genotype and subtype, am I a candidate for a Kuvan loading test?
  • • What are the specific requirements of the REMS program for starting Palynziq?
  • • How does Palynziq differ from a low-phenylalanine diet in terms of its effect on the brain?
  • • What is the long-term plan for monitoring my immune system if I start Palynziq?
  • • Are there any gene therapy clinical trials currently enrolling at this center or nearby?
  • • How would my daily protein intake change if I am a 'super-responder' to Kuvan?

Questions for You

  • • How do I feel about the prospect of daily injections versus the burden of a restricted diet?
  • • Am I comfortable with the safety requirements of carrying an EpiPen and having an observer for my first doses of Palynziq?
  • • What are my main goals for treatment: lower blood Phe levels, more food freedom, or both?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Genetic etiology and clinical challenges of phenylketonuria.

    Elhawary NA, AlJahdali IA, Abumansour IS, et al.

    Human genomics 2022; (16(1)):22 doi:10.1186/s40246-022-00398-9.

    PMID: 35854334
  2. 2

    Phenylketonuria: Current Treatments and Future Developments.

    Lichter-Konecki U, Vockley J

    Drugs 2019; (79(5)):495-500 doi:10.1007/s40265-019-01079-z.

    PMID: 30864096
  3. 3

    International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria.

    Muntau AC, Adams DJ, Bélanger-Quintana A, et al.

    Molecular genetics and metabolism 2019; (127(1)):1-11 doi:10.1016/j.ymgme.2019.04.004.

    PMID: 31103398
  4. 4

    Sapropterin dihydrochloride for phenylketonuria and tetrahydrobiopterin deficiency.

    Blau N

    Expert review of endocrinology & metabolism 2010; (5(4)):483-494 doi:10.1586/eem.10.39.

    PMID: 30780801
  5. 5

    Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria.

    Keskin FN, Şahin TÖ, Capasso R, Ağagündüz D

    Clinical and experimental pediatrics 2023; (66(8)):320-331 doi:10.3345/cep.2022.00584.

    PMID: 36397260
  6. 6

    Tetrahydrobiopterin responsiveness in a series of 53 cases of phenylketonuria and hyperphenylalaninemia in Iran.

    Setoodeh A, Yarali B, Rabbani A, et al.

    Molecular genetics and metabolism reports 2015; (2()):77-79 doi:10.1016/j.ymgmr.2015.01.001.

    PMID: 28649530
  7. 7

    Genotype-phenotype associations in French patients with phenylketonuria and importance of genotype for full assessment of tetrahydrobiopterin responsiveness.

    Jeannesson-Thivisol E, Feillet F, Chéry C, et al.

    Orphanet journal of rare diseases 2015; (10()):158 doi:10.1186/s13023-015-0375-x.

    PMID: 26666653
  8. 8

    Neurotransmitters Disorders with Mild Hyperphenylalaninemia: The Ones That Should Not Be Missed.

    Thoalnoon OA, Kareem AA, Hammoodi HZ

    Archives of Razi Institute 2023; (78(2)):667-673 doi:10.22092/ARI.2022.359480.2431.

    PMID: 37396747
  9. 9

    Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial.

    Muntau AC, Burlina A, Eyskens F, et al.

    Orphanet journal of rare diseases 2021; (16(1)):341 doi:10.1186/s13023-021-01968-1.

    PMID: 34344399
  10. 10

    Beneficial Effect of BH4 Treatment in a 15-Year-Old Boy with Biallelic Mutations in DNAJC12.

    de Sain-van der Velden MGM, Kuper WFE, Kuijper MA, et al.

    JIMD reports 2018; (42()):99-103 doi:10.1007/8904_2017_86.

    PMID: 29380259
  11. 11

    Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria.

    Patrawala M, Kuruvilla M, Li H

    Molecular genetics and metabolism reports 2020; (23()):100575 doi:10.1016/j.ymgmr.2020.100575.

    PMID: 32181140
  12. 12

    Palynziq clinic: One year and 43 patients later.

    Lah M, McPheron M

    Molecular genetics and metabolism 2021; (133(3)):250-256 doi:10.1016/j.ymgme.2021.05.006.

    PMID: 34074593
  13. 13

    Pegvaliase: a novel treatment option for adults with phenylketonuria.

    Mahan KC, Gandhi MA, Anand S

    Current medical research and opinion 2019; (35(4)):647-651 doi:10.1080/03007995.2018.1528215.

    PMID: 30247930
  14. 14

    A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria.

    Hydery T, Coppenrath VA

    Drug target insights 2019; (13()):1177392819857089 doi:10.1177/1177392819857089.

    PMID: 31258325
  15. 15

    Present and future of lipid nanoparticle-mRNA technology in phenylketonuria disease treatment.

    Diaz-Trelles R, Perez-Garcia CG

    International review of cell and molecular biology 2022; (372()):159-174 doi:10.1016/bs.ircmb.2022.04.008.

    PMID: 36064263
  16. 16

    Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).

    Thomas J, Levy H, Amato S, et al.

    Molecular genetics and metabolism 2018; (124(1)):27-38 doi:10.1016/j.ymgme.2018.03.006.

    PMID: 29653686
  17. 17

    Pegvaliase: Immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy.

    Hausmann O, Daha M, Longo N, et al.

    Molecular genetics and metabolism 2019; (128(1-2)):84-91 doi:10.1016/j.ymgme.2019.05.006.

    PMID: 31375398
  18. 18

    Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.

    Burton BK, Longo N, Vockley J, et al.

    Molecular genetics and metabolism 2020; (130(4)):239-246 doi:10.1016/j.ymgme.2020.06.006.

    PMID: 32593547
  19. 19

    Long-Term Metabolic Correction of Phenylketonuria by AAV-Delivered Phenylalanine Amino Lyase.

    Tao R, Xiao L, Zhou L, et al.

    Molecular therapy. Methods & clinical development 2020; (19()):507-517 doi:10.1016/j.omtm.2019.12.014.

    PMID: 33335942
  20. 20

    AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria.

    Richards DY, Winn SR, Dudley S, et al.

    Molecular therapy. Methods & clinical development 2020; (17()):234-245 doi:10.1016/j.omtm.2019.12.004.

    PMID: 31970201
  21. 21

    State-of-the-art 2023 on gene therapy for phenylketonuria.

    Martinez M, Harding CO, Schwank G, Thöny B

    Journal of inherited metabolic disease 2024; (47(1)):80-92 doi:10.1002/jimd.12651.

    PMID: 37401651
  22. 22

    Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.

    Puurunen MK, Vockley J, Searle SL, et al.

    Nature metabolism 2021; (3(8)):1125-1132 doi:10.1038/s42255-021-00430-7.

    PMID: 34294923
  23. 23

    Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial.

    Vockley J, Sondheimer N, Puurunen M, et al.

    Nature metabolism 2023; (5(10)):1685-1690 doi:10.1038/s42255-023-00897-6.

    PMID: 37770764
  24. 24

    Phenylketonuria.

    van Spronsen FJ, Blau N, Harding C, et al.

    Nature reviews. Disease primers 2021; (7(1)):36 doi:10.1038/s41572-021-00267-0.

    PMID: 34017006

This page provides educational information about PKU medications and clinical trials. Always consult your metabolic geneticist or healthcare provider before making changes to your treatment plan or dietary restrictions.

Stay up to date

Get notified when new research about Phenylketonuria is published.

No spam. Unsubscribe anytime.